Organisation paid for research Program year 2025 Source: CMS Open Payments

Sargon Research LLC

Neither a doctor nor a teaching hospital

Research payments

$597,507

34 payments

Through program year 2025, Sargon Research LLC is reported as receiving $597,507 in research payments, across 34 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $261,019 22
2024 Research $303,862 9
2022 Research $31,127 2
2021 Research $1,500 1

Breakdown

Who paid Research payments · program years 2021–2025
  1. Eli Lilly and Company $278,968 4 payments
  2. Janssen Research & Development, LLC $154,000 6 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $86,300 3 payments
  4. Exelixis Inc. $42,343 15 payments
  5. Chiesi USA, Inc. $25,000 1 payment
  6. MorphoSys AG $7,627 2 payments
  7. Genentech, Inc. $3,270 3 payments
Studies the money was for Research payments · program years 2021–2025
  1. A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (Loxo-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Bruin Cll-322) $278,968 4 payments
  2. A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivan $111,900 3 payments
  3. Phase 3 First line in NSCLC $74,500 1 payment
  4. A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma $42,343 15 payments
  5. Efficacy and Safety of Cusa-081 in the Restoration of Dysfunctional Central Venous Access Device (Cvad) Functionality (Ready 2) $25,000 1 payment
  6. A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc $21,836 1 payment
  7. A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer $20,264 2 payments
  8. Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations $11,800 2 payments
  9. A Phase II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Lenalidomide Combined with MOR00208 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) - L-MIND $7,627 2 payments
  10. Atezo Subcut Preference Study Nsclc $3,270 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record